Companies: 10,795·Total market cap: $144.5T
Moderna, Inc.

Moderna, Inc.

MRNANASDAQHealthcare● Active
$47.44
$-4.15(-8.04%)
Market Cap$18.8B
P/E Ratio—
52W High$59.55
52W Low$22.28
Cash on HandFinancialsRevenue

Moderna, Inc. (MRNA) Cash on Hand — Cash & Short-Term Investments

Cash & cash equivalents plus short-term investments from the balance sheet, YoY change, and net cash vs debt context.

MRNA · cash on hand · updated Dec 31, 2025

Core cash position

Cash & Short-Term Investments (CCE + ST Investments)
$5.80B▼ -17.5% vs prior year
FY · as of Dec 31, 2025 · Reported in USD
Cash & Cash Equiv. (CCE)
$2.60B
cashAndCashEquivalents
Short-Term Investments
$3.20B
shortTermInvestments
YoY Change vs Prior Year
-17.5%
vs prior fiscal year
Latest Quarter
$5.21B
Q1 2026
Data Scope & Methodology

Cash on Hand = Cash & Cash Equivalents (CCE) + Short-Term Investments, as reported on the balance sheet (10-K/10-Q). Also referred to as cash reserves or cash position. Not free cash flow.

Source: FMP /balance-sheet-statement · SEC 10-K / 10-Q · Reported in USD

Source: FMP /balance-sheet-statement · SEC 10-K / 10-Q · USDUpdated: December 31, 2025

Net cash vs debt

Cash & ST Investments$5.80BCash on Hand
Total Debt$1.92BTotal Debt
Net Cash / Net Debt+$3.88BNet Cash Position
Cash vs Debt Ratio
Cash 75%Debt 25%

Moderna, Inc. has a net cash position of $3.88B, holding more cash than debt.

Net Cash = Cash & ST Investments − Total Debt$5.80B − $1.92B = +$3.88B

Cash on hand history

YoY Increase
YoY Decrease
Latest Year
MRNA annual cash on hand history · Cash & Short-Term Investments · Source: FMP /balance-sheet-statement

Annual cash on hand by year

DateCash & ST InvestmentsYoY Change
Dec 31, 2025Latest$5.80B-17.5%
Dec 31, 2024$7.03B-18.4%
Dec 31, 2023$8.60B-13.1%
Dec 31, 2022$9.90B-7.7%
Dec 31, 2021$10.73B+132.8%
MRNA cash on hand annual historical data · Cash & Short-Term Investments per balance sheet (10-K/10-Q) · Reported in USD · Source: FMP /balance-sheet-statement

Healthcare Sector Cash Reserves Comparison

#CompanyCash & ST Inv.Cash/MCap
#1
UnitedHealth Group Incorporated
UnitedHealth Group Incorporated
UNH
$28.12B7.8%#2
Johnson & Johnson
Johnson & Johnson
JNJ
$20.10B3.6%#3
Eli Lilly and Company
Eli Lilly and Company
LLY
$7.27B0.7%
#4
Moderna, Inc.
Moderna, Inc.YOU
MRNA
$5.80B30.8%
#5
AbbVie Inc.
AbbVie Inc.
ABBV
$5.26B1.3%
Healthcare sector cash reserves · Source: FMP /balance-sheet-statement + /profile · Sorted by Cash desccompanies with most cash on hand →

About cash on hand & methodology

Moderna, Inc. (MRNA) cash on hand as of December 31, 2025 is $5.80B, comprising $2.60B in cash and cash equivalents (CCE) plus $3.20B in short-term investments — reported as Moderna, Inc. cash and short-term investments on the balance sheet (10-K filing). Also referred to as Moderna, Inc. cash reserves or cash position.

Moderna, Inc. annual cash on hand history shows decreased -17.5% in 2025: decreased -17.5% in 2025. Moderna, Inc. cash reserves in 2025 reflect the company's capital allocation strategy.

Moderna, Inc. carries total debt of $1.92B against cash of $5.80B, resulting in a net cash position of +$3.88B. For the full balance sheet, see the Financials → Balance Sheet tab.

Figures tie to SEC 10-K/10-Q balance sheet disclosures and FMP /balance-sheet-statement where noted.
Financial statementsFree cash flowNet incomeRevenueMarket capP/E ratioEarningsPrice history

Frequently asked questions

MRNA cash on hand · 5 questions

As of December 31, 2025, Moderna, Inc. (MRNA) has $5.80B in cash on hand — defined as cash and short-term investments on the balance sheet. This includes $2.60B in cash and cash equivalents (CCE) plus $3.20B in short-term investments. Latest quarter (March 31, 2026): $5.21B. Data sourced from the annual 10-K filing via FMP.

MRNA cash on handMRNA cash reservesMRNA cash 2025how much cash does MRNA have

▸ Source: FMP /balance-sheet-statement · US GAAP · Moderna, Inc. · Moderna, Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: December 31, 2025